Lung Cancer

In light of recent advancements, the current paradigm for choosing first-line therapy for patients with metastatic non–small cell lung cancer who do not harbor an actionable driver oncogene depends upon PD-L1 expression level and histology.

Roy S. Herbst, MD, PhD, discusses where future research is headed for immunotherapy in lung cancer.

Nasser Hanna, MD, Tom and Julie Wood Family Foundation Professor of Lung Cancer Clinical Research, at Indiana University Melvin and Bren Simon Cancer Center, discusses the efficacy of consolidation immunotherapy in patients with stage III non–small cell lung cancer.

Roy S. Herbst, MD, PhD, chief of medical oncology, professor of medicine, Yale Cancer Center, Smilow Cancer Hospital, discusses mechanisms of immune resistance for patients with lung cancer.

Although driver mutations have been identified for significant NSCLC subsets, patients with metastatic disease benefit from broad panel next-generation sequencing testing because of the growing clinical relevance of less common alterations and gene signatures.

Roman Perez-Soler, MD, chairman of the Department of Oncology and chief of the Division of Medical Oncology at Montefiore Medical Center, discusses the efficiency of next-generation sequencing in lung cancer.

D. Ross Camidge, MD, PhD, discusses the crowded landscape of oncogene-driven non­–small cell lung cancer.

Hossein Borghaei, DO, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the evolving second line of treatment in small cell lung cancer.

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses adjuvant systemic therapy in patients with non–small cell lung cancer.

D. Ross Camidge, MD, PhD, director of thoracic oncology, University of Colorado, discusses optimal treatment regimens for patients with EGFR-positive non–small cell lung cancer.

Balazs Halmos, MD, MS, discusses overcoming acquired resistance and other next steps needed to advance the oncogene-driven non–small cell lung cancer paradigm.

Stephen Liu, MD, associate professor of medicine, Division of Hematology and Oncology, Georgetown University Medical Center, discusses the frontline treatment of ALK-positive non–small cell lung cancer (NSCLC).

Hossein Borghaei, DO, MS, discusses current and potential therapeutic approaches for patients with non-oncogene driven lung cancer who progress on frontline treatment.

Alexander E. Drilon, MD, discusses developing markers in the non–small cell lung cancer paradigm.

Balazs Halmos, MD, discusses the latest developments in the treatment paradigm for patients with squamous cell non–small cell lung cancer.

H. Jack West, MD, thoracic oncologist, Swedish Cancer Institute of Swedish Medical Center, discusses the FDA approval of lorlatinib for the treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC).

Ravi Salgia, MD, PhD, Arthur & Rosalie Kaplan Chair in Medical Oncology, associate director for clinical sciences at City of Hope, discusses the FDA approval of lorlatinib for use in patients with ALK-positive metastatic non–small cell lung cancer.

The FDA has granted lorlatinib an accelerated approval for the treatment of patients with ALK-positive metastatic non–small cell lung cancer (NSCLC) who have progressed on 1 or more ALK tyrosine kinases inhibitors (TKIs).

Mary Pasquinelli, MS, APRN, discusses the pivotal role of nurses in lung cancer care.

Balazs Halmos, MD, MS, director of thoracic oncology and director of clinical cancer genomics, Montefiore Medical Center, discusses second-line treatment for patients with metastatic squamous non–small cell lung cancer (NSCLC).

D. Ross Camidge, MD, PhD, a professor of medical oncology at the University of Colorado, discusses the FDA approval of first-line pembrolizumab (Keytruda) in metastatic squamous non–small cell lung cancer regardless of PD-L1 expression.

The FDA has approved first-line pembrolizumab for use in combination with carboplatin and either paclitaxel or nab-paclitaxel for the treatment of patients with metastatic squamous non–small cell lung cancer.

Charles M. Rudin, MD, PhD, chief, Thoracic Oncology Service, co-director, Druckenmiller Center for Lung Cancer Research, Sylvia Hassenfeld Chair in Lung Cancer Research, Memorial Sloan Kettering Cancer Center, discusses the success of immunotherapy in small cell lung cancer.

Hossein Borghaei, DO, MS, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the current landscape of immunotherapy in non–small cell lung cancer (NSCLC).

Missak Haigentz, MD, discusses the impact of EGFR TKIs on the treatment of patients with non–small cell lung cancer.